Orchestra BioMed Holdings, Inc. OBIO
5.99 USD -0.02 (-0.42%)
Nov 12, 2026, 2:18 PM EST
5.70 Day range 6.08
3.46 52-week range 6.50
- YTD
- +44.22%
- 1 year
- +35.41%
News
zacks.com Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.4 per share a year ago.
benzinga.com Orchestra BioMed Hldgs Q3 EPS $(0.30) Beats $(0.40) Estimate, Sales $91.000K Miss $106.000K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.40) by 25 percent. This is a 25 percent increase over losses of…
globenewswire.com Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized. BACKBEAT Trial primary endpoint data planned to be…
globenewswire.com Orchestra BioMed Announces Pricing of Public Offering NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact…
benzinga.com Orchestra BioMed Commences Common Stock Offering; Terms Not Disclosed Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
benzinga.com Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results U.S. stocks fell Thursday as the Dow dropped 300+ points; Macy’s slid on weak guidance, while oil rose and producer prices accelerated.
benzinga.com Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
benzinga.com This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded SFNC, OBIO, and more.
benzinga.com BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
benzinga.com Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10 Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
benzinga.com Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10 B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
benzinga.com HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.- benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
benzinga.com Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41) by 19.51 percent. This is a 32.65 percent increase over losses…- benzinga.com Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2 Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
- benzinga.com Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty…
- benzinga.com Orchestra BioMed Receives $20M Investment From Medtronic Under Previously Announced Strategic Financing Agreement Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval…
benzinga.com Orchestra BioMed Announces Second FDA Breakthrough Device Designation For AVIM Therapy Specific To Patients With Uncontrolled Hypertension Despite Use Of Medications, Along With An Indication For A Pacemaker Together, the two BDDs for AVIM Therapy cover indications that encompass both the broader population of patients with uncontrolled hypertension despite medication and increased cardiovascular risk as…- benzinga.com Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.39) by 166.16 percent. This is a 160.47 percent increase over…
- benzinga.com Orchestra BioMed Anticipates Up To $21M In Cash Proceeds From Haemonetics Regarding Vivasure Acquisition Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing…
benzinga.com Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts - benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
- benzinga.com TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15 TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces Price Target of $15.
- benzinga.com Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
- benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
- benzinga.com Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.21 percent. This is a 2.44 percent increase over losses…
- benzinga.com Orchestra BioMed Enters $30M Agreement With Terum To Treat Coronary Artery Disease Globally Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
- benzinga.com Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic…- benzinga.com OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025 | Fellow Shareholders: Recent clinical announcements related to our…
- benzinga.com Orchestra BioMed Reports Long-Term, Reversible Blood Pressure Benefits Of AVIM Therapy; Results Support Durable, Programmable Treatment For Uncontrolled Hypertension Results from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show blood pressure-lowering effects are sustained for years after activation,…
- benzinga.com HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10 HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - benzinga.com Orchestra BioMed Publishes AVIM Therapy Clinical Data In JACC: Advances Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation ("AVIM") therapy on MODERATO II study patients with diastolic dysfunction, a key component in the…
- benzinga.com Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
- benzinga.com Orchestra BioMed Hldgs Q2 EPS $(0.50) Beats $(0.51) Estimate, Sales $836.000K Beat $695.600K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.51) by 0.99 percent. This is a 11.11 percent decrease over losses…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.- benzinga.com Orchestra BioMed Secures $111M From Medtronic, Ligand to Advance Heart and Artery Treatments Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships,…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Orchestra BioMed Announces Proposed Public Offering; No Size Or Amount Disclosed Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships,…
- benzinga.com Orchestra BioMed Holdings Presents Key Clinical Insights Into Role Of AVIM Therapy For Treatment Of High-Risk Hypertension At Congenital, Structural, And Valvular Heart Disease Interventions 2025 Meeting Presentation underscores unique potential for atrioventricular interval modulation ("AVIM") therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction…